Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Immunic Inc (IMUX)

Immunic Inc (IMUX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing

NEW YORK, NY / ACCESSWIRE / December 3, 2024 / Investor Summit Group, committed to advancing the MicroCap and SmallCap investment community, announces that the November 21, 2024 Winter Investor Summit...

IMRN : 1.9600 (-1.75%)
ULY : 0.5030 (-4.14%)
IMUX : 1.0000 (-3.85%)
NMTC : 0.7582 (+0.03%)
SNGX : 2.95 (-4.22%)
TMG.VN : 0.190 (unch)
BLGO : 0.1950 (+8.64%)
FET : 14.21 (-1.80%)
ACFN : 18.0000 (-0.55%)
NRBO : 2.36 (+0.43%)
TGCB : 0.0800 (-15.79%)
SOTK : 4.23 (-4.73%)
Immunic: Q3 Earnings Snapshot

Immunic: Q3 Earnings Snapshot

IMUX : 1.0000 (-3.85%)
Immunic: Q2 Earnings Snapshot

Immunic: Q2 Earnings Snapshot

IMUX : 1.0000 (-3.85%)
Immunic Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis at the United European Gastroenterology Week 2023

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...

IMUX : 1.0000 (-3.85%)
Immunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...

IMUX : 1.0000 (-3.85%)
Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...

IMUX : 1.0000 (-3.85%)
Stock Index Futures Climb on Dovish Fed Comments, PepsiCo Earnings on Tap

December S&P 500 futures (ESZ23) are up +0.20%, and December Nasdaq 100 E-Mini futures (NQZ23) are up +0.26% this morning as comments from Fed officials bolstered bets that the U.S. central bank may stand...

ESZ23 : 4,694.27s (-0.58%)
NQZ23 : 16,530.23s (-0.07%)
ZS : 187.38 (+2.28%)
NOC : 469.54 (+0.52%)
LMT : 489.02 (+1.95%)
DAL : 60.93 (+0.91%)
AAL : 16.88 (+1.44%)
DDOG : 149.46 (+1.72%)
PEP : 152.79 (+0.87%)
ELIS.FP : 18.640 (+0.76%)
IMUX : 1.0000 (-3.85%)
AKRO : 29.34 (+3.31%)
Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis

– 24-Week Data from First Half of Patients Shows Improvements in Biomarker NfL, Consistent Throughout the Overall Progressive Multiple Sclerosis Population as...

IMUX : 1.0000 (-3.85%)
Immunic to Participate in Scientific Conferences in October

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...

IMUX : 1.0000 (-3.85%)
Immunic to Participate in Industry and Investor Conferences in September

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for...

IMUX : 1.0000 (-3.85%)

Barchart Exclusives

Elon Musk Didn't Expect Tesla or SpaceX to be Succesful, But He Did It Because They "Were Important Enough to do Anyway"
In a reflection on his entrepreneurial journey, tech magnate Elon Musk offered a glimpse into the mindset that led him to launch two of the world’s most groundbreaking ventures: Tesla and SpaceX. Speaking on his early years of founding these companies, Musk said, “I always have optimism, but I’m realistic.... Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar